Skip to main content

Table 1 Clinical and demographic characteristics of myositis patients analyzed in the intervention group and control group

From: The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up

Parameters

Intervention group

(n = 27)

Control group

(n = 23)

p-value

Gender: female/male, n (%)

22 (81)/5 (19)

21 (91)/2 (9)

0.429

Age, years

56.0 (41.0–68.0)

58.0 (52.0–65.0)

0.513

Clinical features

 Disease duration, years

6.0 (2.0–9.4)

2.8 (1.4–8.3)

0.266

 IIM subtype, n (%): PM/DM/IMNM

12 (44)/10 (37)/5 (19)

10 (44)/11 (48)/2 (8)

0.064

 IIM-associated symptoms, n (%):

  MW/D/SR/MH/

27 (100)/5 (19)/2 (7)/1 (4)/

23 (100)/7 (30)/4 (17)/3 (13)/

1.000/0.319/0.379/0.306/

  RP/A/ILD/CI

3 (11)//1 (4)/9 (33)/4 (15)

7 (30)//1 (4)/7 (30)/5 (22)

0.081/1.000/1.000/0.477

  MMT-8 total score

56.0 (48.0–65.0)

64.0 (55.0–71.0)

0.024

  MITAX

0.2 (0.1–0.3)

0.2 (0.1–0.4)

0.120

  MDI extent

0.1 (0.0–0.1)

0.1 (0.0–0.1)

0.355

Laboratory features

 Autoantibodies, n (%):

  ANA/Mi-2/TIF1/MDA5/

17 (63)/2 (7)/0 (0)/0 (0)/

14 (61)/1 (4)/2 (9)/1 (4)/

1.000/1.000/0.186/0.437/

  SAE/NXP2/SRP/HMGCR/Jo-1/

0 (0)/2 (7)/1 (4)/3 (11)/3 (11)/

1 (4)/1 (4)/2 (8)/0 (0)/7 (30)/

0.437/1.000/0.574/1.000/0.081/

  PM-Scl/snRNP/Ku/Ro

2 (7)/2 (7)/2 (7)/11 (41)

2 (9)/0 (0)/0 (0)/8 (35)

1.000/1.000/1.000/0.497

  CRP, mg/L

3.0 (1.7–4.6)

4.1 (1.4–8.2)

0.403

  ESR, mm/h

13.0 (7.0–26.0)

15.0 (9.0–30.0)

0.550

  CK, μkat/L

4.0 (1.8–8.9)

1.3 (0.8–3.9)

0.005

  LD, μkat/L

4.0 (3.5–4.9)

3.7 (3.4–4.7)

0.626

  Myoglobin, μg/L

112.3 (67.0–299.5)

78.0 (47.6–128.2)

0.108

Current treatment

 Prednisone equivalent dose, mg/day

6.0 (1.3–10.0)

15.0 (5.0–30.0)

0.021

 MTX/CPA/AZA/CSA/

10 (37)/0 (0)/7 (26)/4 (15)/

7 (30)/1 (4)/2 (9)/2 (9)/

0.767/0.460/0.152/0.674/

 LEF/MMF/SAS/HQ/TAC/

0 (0)/2 (7)/1 (4)/0 (0)/1 (4)/

2 (9)/0 (0)/0 (0)/1 (4)/0 (0)/

0.207/0.493/1.000/1.000/1.000/

 RTX/IVIg, n (%)

0 (0)/0 (0)

0 (0)/0 (0)

1.000/1.000

  1. Acronyms: Data are presented as median (inter-quartile range) unless stated otherwise. Statistically significant differences (p < 0.05) are marked in bold
  2. IIM idiopathic inflammatory myopathy, PM polymyositis, DM dermatomyositis, IMNM immune-mediated necrotizing myopathy, MW muscle weakness, D dysphagia, SR skin rash, MH mechanic’s hands, RP Raynaud’s phenomenon, A arthritis, ILD interstitial lung disease, CI cardiac involvement, MMT-8 Manual Muscle Testing of eight muscles, MITAX Myositis Intention to Treat Activity Index, MDI Myositis Damage Index, ANA antinuclear antibodies, Mi-2 antinuclear helicase 218/240 kDa, TIF1 anti-TIF1 (transcription intermediary factor-1), MDA5 anti-CADM-140 (melanoma differentiation-associated gene 5), SAE anti-SUMO1 (small ubiquitin-like modifier 1) activating enzyme, NXP2 anti-NXP2 (nuclear matrix protein), SRP anti-signal recognition particles, HMGCR anti-3-hydroxy-3-methylglutaryl-CoA reductase, Jo-1 anti-histidyl-tRNA synthetase, PM-Scl anti-Pm-Scl (anti-core complex 11-16 proteins), snRNP small nuclear ribonucleoprotein, Ku anti-Ku (against the nuclear DNA-dependent protein kinase subunit), Ro anti-Ro (52/60 kDa, against cytoplasmic RNA and associated peptides), CRP C-reactive protein, ESR erythrocyte sedimentation rate, CK creatine kinase, LD lactate dehydrogenase, MTX methotrexate, CPA cyclophosphamide, AZA azathioprine, CSA cyclosporin A, LEF leflunomide, MMF mycophenolate mofetil, SAS sulphasalazine, HQ hydroxychloroquine, TAC tacrolimus, RTX rituximab, IVIg intravenous immunoglobulins